Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Where Will Novavax Be in 1 Year?

By Adria Cimino - Dec 19, 2020 at 6:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered for Novavax's science this year. Next year, they'll cheer for its revenue.

At the start of 2020, Novavax ( NVAX -0.60% ) shares were trading at $3.98, and the idea of a commercialized product seemed far off. Then two elements sent the shares into the stratosphere and spurred hope for not one -- but two -- marketed products in the near term. The company said its flu vaccine candidate met all primary endpoints in a pivotal trial. At the same time, Novavax began developing a coronavirus vaccine.

The stock has skyrocketed more than 2,900% winning the title of this year's top performer -- over all companies in all industries. Looking ahead, we might ask ourselves where this biotech-on-the-move may be a year from now. Will this year's work begin to bear fruit? Let's consider what Novavax has accomplished so far and what's next on the agenda.

Man wearing medical gloves holding cash and vaccine vials

Image source: Getty Images.

One of the leading players

Novavax won't be first to market with a coronavirus vaccine. Pfizer ( PFE -0.62% ) already claimed that title when it received Emergency Use Authorization (EUA) for its vaccine candidate this month. And that's fine. Global need for a vaccine means there is room for more than one -- now and into the future.

Novavax still remains one of the leading players in the vaccine race. It is among the 13 programs in phase 3 trials. The company expects interim data in the early part of the first quarter from its U.K. phase 3 trial. Novavax says the results will support emergency use authorization requests. If Novavax follows in Pfizer's footsteps from a timeline perspective, its coronavirus vaccine candidate could enter the market in a matter of weeks.

That means the biotech company could start generating revenue in the first half of the year. So far, Novavax has agreements to supply at least 286 million doses to various countries, including the U.S. Novavax hasn't specified how much it is charging for its vaccine. But let's use the price the U.S. is paying as a general guide. The government offered Novavax $1.6 billion in exchange for 100 million doses of vaccine. That's $16 a dose. At that price, all of Novavax's orders so far would generate more than $4.5 billion in revenue. And Novavax is ramping up capacity to 2 billion doses by the middle of the year. That would represent $32 billion in potential revenue -- if orders match Novavax's full capacity.

Moving along to Novavax's flu vaccine candidate: In phase 3, NanoFlu met primary endpoints of general safety and non-inferior immune response compared with Sanofi's ( SNY 0.17% ) Fluzone Quadrivalent. And it even demonstrated higher antibody responses than those produced by Fluzone. The company recently assembled a team to shepherd NanoFlu through the regulatory approval process.

Novavax hasn't said when it will file for approval, but it's likely that will happen in the coming year. If the regulatory process goes smoothly, NanoFlu revenue could be something to look for in 2022.

Progress on a flu/coronavirus vaccine

And finally, a year from now, Novavax might be making progress on its plan to develop a combined flu/coronavirus vaccine. This would be for use after the pandemic. If the timeline resembles that of the coronavirus vaccine candidate, Novavax may be testing the potential product in humans by this time next year. If the timeline is more traditional, though, the program might only advance into preclinical tests during the coming 12 months.

So, a year from now, Novavax may have a coronavirus vaccine on the market, billions of dollars in product revenue, a soon-to-be commercialized flu vaccine, and a flu/coronavirus vaccine in human trials.

What does this mean for investors? In 2020, investors placed bets on Novavax's future. Risk was (and is still) high, and so was reward. Once the company has a product on the market and is generating revenue, risk will be lower. But the potential for rewards won't go away. Wall Street's average 12-month share price forecast calls for a 50% gain from today's level. Potential revenue from a coronavirus vaccine is the catalyst to take the shares to that point -- or maybe even higher.

And the story isn't over there for this biotech stock. NanoFlu and a possible flu/coronavirus vaccine could be the catalysts to power gains well into 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$181.75 (-0.60%) $-1.10
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.40 (-0.62%) $0.32
Sanofi Stock Quote
Sanofi
SNY
$47.99 (0.17%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
145%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.